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S U M M A R Y
Objectives: To investigate the dynamics and clinical signiﬁcance of hepatitis B surface antigen (HBsAg)
levels in hepatitis B e antigen (HBeAg)-negative acute-on-chronic liver failure (ACLF) patients receiving
lamivudine.
Methods: Fifty-nine nucleoside-naı¨ve patients with HBeAg-negative ACLF were enrolled and treated
with 100 mg of lamivudine daily. The dynamics of serum levels of HBsAg and HBV DNA were analyzed at
baseline and at week 12, or before death if the patient died within 12 weeks.
Results: Twenty-eight cases died within 12 weeks and 31 cases survived after treatment. HBsAg levels of
patients who survived were signiﬁcantly higher than those of patients who died both pre- and post-
treatment (all p < 0.05). There were 33 patients with pretreatment HBsAg levels above 4000 COI and 26
cases with levels below this value. The 12-week survival rate of those with levels 4000 COI was
signiﬁcantly higher than that of patients with levels <4000 COI (66.7% (22/33) vs. 34.5% (9/26), Chi-
square = 5.991, p = 0.014). Regardless of the pretreatment HBsAg level, there was no signiﬁcant
difference in HBV DNA levels between survivors and those who died, and no correlation was observed
between HBV DNA and HBsAg (all P > 0.05).
Conclusions: Changes in HBsAg level could be a useful parameter for predicting the short-term outcome
of lamivudine monotherapy in HBeAg-negative ACLF.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Acute-on-chronic liver failure (ACLF) is a critical clinical
syndrome involving acute hepatic insult manifesting as jaundice
and coagulopathy, complicated within 4 weeks by ascites and/or
encephalopathy in a patient with previously diagnosed or undiag-
nosed chronic liver disease.1 Chronic hepatitis B virus (HBV)
infection is one of the major causes of ACLF in Asia.2 The proportion
of such patients who are hepatitis B e antigen (HBeAg)-negative was
reported to be 71.74% in 2008 in China and is increasing.3 Previous
studies have demonstrated that in chronic hepatitis B and in HBV-
related ACLF, active replication of HBV DNA is a major pathogenesis
initiating factor and a cause of progression.4,5 Lamivudine (2,3-
dideoxy-3-thiacytidine) is a potent and highly selective inhibitor of
HBV DNA polymerase used to clear the liver of covalently closed
circular (ccc) DNA,6–8 and has been shown to be effective in the* Corresponding author. Tel.: +86 20 85253059; fax: +86 20 85252559.
E-mail address: yankee2@21cn.com (J. Lai).
http://dx.doi.org/10.1016/j.ijid.2013.12.018
1201-9712  2014 The Authors. Published by Elsevier Ltd on behalf of International Sotreatment of chronic hepatitis B.2,8 Furthermore, Chan et al.9,10 and
Gramenzi et al.11 have reported that changes in hepatitis B surface
antigen (HBsAg) levels could be a useful parameter for assessing the
response to lamivudine in chronic hepatitis B, because it is
correlated with the number and expression activity of the HBV
genomes in the hepatocytes. However the role of HBsAg during
lamivudine treatment in ACLF has not been well investigated. The
aim of this study was to retrospectively investigate the dynamics
and clinical signiﬁcance of serum HBsAg levels in HBeAg-negative
ACLF patients receiving lamivudine.
2. Materials and methods
Clinical data of 59 patients with HBeAg-negative ACLF treated
between January 2010 and July 2012 in our department were
collected; these patients had not been treated previously with a
nucleoside analog. The inclusion criteria were: (1) acute hepatic
insult manifesting as jaundice (serum bilirubin 5 mg/dl and
coagulopathy (international normalized ratio (INR) 1.5 orciety for Infectious Diseases. Open access under CC BY-NC-ND license.
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ascites and/or encephalopathy;1 (2) the presence of HBsAg in the
serum for at least 6 months; (3) HBeAg negative before treatment;
and (4) evidence of active viral replication, as documented by
measurable HBV DNA in the serum (2.0 log IU/ml). The exclusion
criteria were the following: (1) super-infection or co-infection with
hepatitis virus A (HAV), C (HCV), D (HDV), or E (HEV), Epstein–Barr
virus, cytomegalovirus, or HIV; (2) a previous course of any
antiviral, immunomodulator, or cytotoxic/immunosuppressive
therapy for chronic hepatitis within at least the preceding 12
months; (3) evidence of decompensated liver disease before
enrollment; (4) hepatocellular carcinoma diagnosed by ultraso-
nography or computed tomography; (5) coexistence of any other
serious disease such as autoimmune hepatitis, alcoholic liver
disease, drug hepatitis, or Wilson’s disease; and (6) malignant
jaundice induced by obstructive jaundice or hemolytic jaundice
and prolonged prothrombin time induced by blood system disease.
All patients were treated with lamivudine orally (100 mg/day,
Epivir-HBV, GlaxoSmithKline). Serum levels of HBsAg and HBV DNA
were detected at baseline. If a patient died within 12 weeks, the day
of death was regarded as the primary endpoint to calculate the
duration of therapy. Post-treatment levels of HBsAg and HBV DNA
were collected before death. If the patient survived, lamivudine
monotherapy was continued except in cases of severe side effects or
resistance. However we only analyzed the post-treatment levels of
HBsAg and HBV DNA that were detected at week 12 in this study.
All patients were followed up and the outcome of treatment
was recorded. The date and cause of death were documented for
each patient who died.
The study was conducted in accordance with the principles of the
Declaration of Helsinki, the Good Clinical Practice guidelines, and
applicable local regulatory requirements. Written informed consent
was obtained from all patients or their relatives before treatment.
2.1. Laboratory measurements
Serum HBsAg was measured by electrochemical immunoassay
(Elecsys 2010; Roche Diagnostics, Mannheim, Germany). The cut-
off value was >1 cut-off index (COI). Serum HBeAg was detected by
AxSYM automatic rapid immunoassay system (Abbott Diagnos-
tics). Serum HBV DNA was measured by PCR assay (Amplicor HBV
Monitor Test; Daan Gene Diagnostics, Guangzhou, China). The
detection limit was 2.0 log IU/ml. The patients were also tested
for anti-HAV IgM, anti-HAV IgG, anti-HCV IgG, HVC RNA
quantitation, anti-HEV IgM, and anti-HEV IgG at baseline.
The tyrosine, methionine, aspartate, and aspartate (YMDD)
mortify mutant was detected by PCR ﬂuorescence for mixed viralTable 1
Comparisons between patients who survived and patients who died
Characteristic Survived 
n 31 
Age, years 43.16  13.76 
Therapy duration, days >90a
HBsAg level, COI
Pretreatment 6506  3281 
Post-treatment 6459  1983 
t 0.063 
p-Value 0.950 
Post-treatment increased, n 17 
Post-treatment decreased, n 14 
HBV DNA level, log IU/ml
Pretreatment 4.99  1.69 
Post-treatment 2.73  1.05 
t 5.186 
p-Value <0.001 
HBsAg, hepatitis B surface antigen; COI, cut-off index; Pretreatment, before beginning 
a All survivors continued lamivudine treatment; post-treatment HBsAg levels were dgenotype populations (wild-type and mutant virus) at baseline and
follow-up. The detection limit was 3.00 log copies/ml.
2.2. Statistical analysis
Patient data were presented as the mean  standard deviation.
Group means were compared by t-test. Frequencies were compared
using the Chi-square test. The correlation analysis was done using
Spearman’s rho correlation coefﬁcient. All statistical tests were two-
tailed and p-values of <0.05 were considered to be statistically
signiﬁcant. All analyses were performed using SPSS for Windows
version 18.0 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Demographic characteristics of the patients at baseline
The clinical data of 59 patients were eligible for this
retrospective analysis. For each patient, the serum HBV DNA level
was above 2.0 log IU/ml and HBsAg level was above 1 COI at
baseline.
3.2. Post-treatment characteristics of the patients
After treatment, 28 patients died from liver failure within 12
weeks and 31 patients survived. The causes of death were all
related to liver failure. There was no signiﬁcant difference in age
between the survivors and those who died (t = 1.356, p = 0.181)
(Table 1), nor was there a difference in age between patients with
pretreatment HBsAg levels 4000 COI and patients with levels
<4000 COI (t = 0.678, p = 0.868) (Table 2).
The HBsAg level was not signiﬁcantly decreased after short-
term lamivudine therapy (all p > 0.05). However, HBsAg levels of
survivors were signiﬁcantly higher than those of patients who
died, both pre- and post-treatment (all p < 0.05) (Tables 1 and 3).
The 12-week survival rate of patients with pretreatment HBsAg
levels 4000 COI was signiﬁcantly higher than that of cases with
levels <4000 COI (Chi-square = 5.991, p = 0.014) (Table 2).
Furthermore, the ratio of post-treatment HBsAg increasing in
the survivors was signiﬁcantly higher than in the patients who
died (Chi-square = 4.157, p = 0.041) (Table 1). Table 3 shows that in
patients with pretreatment HBsAg levels 4000 COI, the ratio of
post-treatment HBsAg increasing for survivors was signiﬁcantly
higher than for those who died (Chi-square = 3.882, p = 0.049).
However, no signiﬁcant difference was found in patients with
pretreatment HBsAg levels <4000 COI (Chi-square = 0.042,
p = 0.837).Died t p-Value
28
47.96  12.76 1.356 0.181
28.10  12.02
4747  3311 2.202 0.049
3622  3514 2.353 0.036
0.898
0.376
8
20
5.66  1.67 1.478 0.145
3.05  1.29 0.663 0.513
3.917
<0.001
lamivudine; HBV, hepatitis B virus.
etected at week 12.
Table 2
Comparisons between patients with pretreatment HBsAg levels above and below 4000 COI
Characteristic Pretreatment HBsAg level, COI t p-Value
4000a <4000b
n 33 26
Age, years 43.73  13.70 44.37  12.52 0.678 0.868
12-week survival rate, n (%)c 22 (66.7) 9 (34.5)
HBsAg level, COI
Pretreatment 6423  1842 2104  1133 5.438 <0.001
Post-treatment 6226  3427 691  511 4.274 <0.001
t 2.253 1.652
p-Value 0.802 0.142
HBV DNA level (log IU/ml)
Pretreatment 5.15  1.43 5.17  2.20 0.041 0.966
Post-treatment 2.84  1.15 3.13  1.17 0.667 0.507
t 5.49 0.667
p-Value <0.001 <0.001
HBsAg, hepatitis B surface antigen; COI, cut-off index; Pretreatment, before beginning lamivudine; HBV, hepatitis B virus.
a No signiﬁcant correlation was observed between HBsAg and HBV DNA in patients with pretreatment HBsAg levels above 4000 COI (r = 0.076, p = 0.679).
b No signiﬁcant correlation was observed between HBsAg and HBV DNA in patients with pretreatment HBsAg levels below 4000 COI (r = 0.191, p = 0.434).
c A signiﬁcant difference was found in the 12-week survival rate between patients with pretreatment HBsAg levels above 4000 COI and those with levels below 4000 COI
(Chi-square = 5.991, p = 0.014).
Table 3
Comparisons among patients with different pretreatment HBsAg levels
Characteristic Survived Died t p-Value
HBsAg level 4000 COI
n 22 11
Pretreatment HBsAg, COI 8450  1282 8258  2273 2.253 0.802
Post-treatment HBsAg, COI 7009  2498 6745  1280 1.652 0.142
t 0.596 2.096
p-Value 0.376 0.045
Post-treatment increased, n 14 3
Post-treatment decreased, n 8 8
Pretreatment HBV DNA, log IU/ml 5.26  1.50 4.73  0.62 2.026 0.052
Post-treatment HBV DNA, log IU/ml 2.99  1.19 3.35  1.70 0.420 0.683
t 4.119 2.216
p-Value <0.001 0.049
HBsAg level <4000 COI
n 9 17
Pretreatment HBsAg, COI 2196  1274 2000  1082 0.358 0.725
Post-treatment HBsAg, COI 3549  1782 1161  1125 0.534 0.035
t 1.543 1.440
p-Value 0.154 0.170
Post-treatment increased, n 3 5
Post-treatment decreased, n 6 12
Pretreatment HBV DNA, log IU/ml 4.74  2.40 5.92  2.05 1.482 0.156
Post-treatment HBV DNA, log IU/ml 3.01  1.06 3.42  1.38 4.462 0.655
t 2.083 2.671
p-Value 0.039 0.017
HBsAg, hepatitis B surface antigen; COI, cut-off index; Pretreatment, before beginning lamivudine; HBV, hepatitis B virus.
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serum HBV DNA levels (all p < 0.05). No signiﬁcant difference was
found in HBV DNA levels between the patients who survived and
those who died, both pre- and post-treatment (all p > 0.05)
(Table 1). Neither was a difference found among the patients with
different pretreatment HBsAg levels (all p > 0.05) (Tables 2 and 3).
No correlation was observed between HBV DNA and HBsAg (all
p > 0.05) (Table 2).
3.3. YMDD mutations
None of the patients showed evidence of YMDD mutations at
baseline or during treatment.
3.4. Safety
No serious adverse event was attributed to lamivudine. All the
patients tolerated the treatment without modiﬁcation of the dose
or early discontinuation.4. Discussion
HBsAg is the glycosylated envelope protein of the mature HBV
virion. Recently, there has been renewed interest in the
quantiﬁcation of HBsAg with the observation of its possible
association with the level of ccc DNA.12,13 However, this may vary
in the different phases of the disease.14–16Werle-Lapostolle et al.12
and Chan et al.17,13 reported a strong correlation between ccc DNA
and quantitative HBsAg, serum HBV DNA level in chronic hepatitis
B. Chan et al.17,13 also suggested that serial monitoring of HBsAg
levels might act as an additional marker to evaluate the response to
treatment during lamivudine therapy in chronic hepatitis B,
because it may indirectly reﬂect the clearance of ccc DNA inside the
hepatocytes. On the other hand, Li et al.18 reported that the level of
HBsAg was not directly correlated with the serum level of HBV
DNA or with the severity of the disease in HBV-related ACLF. To
date this has remained controversial and only a few studies have
investigated the role of HBsAg levels during lamivudine mono-
therapy in HBeAg-negative ACLF.
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2010 assay (Roche Diagnostics), which is an HBsAg II test. The
result was determined automatically by the Elecsys software, by
comparing the electrochemiluminescence signal obtained from
the reaction product of the sample with the signal of the cut-off
value previously obtained by HBsAg calibration. Although this was
a half-quantitative detection, previous studies have demonstrated
that the Elecsys 2010 assay is a highly sensitive and speciﬁc
screening assay and can reliably quantify HBsAg in the most
important and clinically relevant HBV mutants and genotypes in
Asia.19–21
Our study showed that serum levels of HBV DNA decreased
signiﬁcantly after short-term lamivudine therapy (all p < 0.05). No
signiﬁcant difference was found in HBV DNA levels between the
patients who survived and those who died, both pre- and post-
treatment (all p > 0.05) (Table 1). Neither was a difference found
among the patients with different pretreatment HBsAg levels (all
p > 0.05) (Tables 2 and 3). However, serum levels of HBsAg did not
decrease signiﬁcantly after treatment in either the patients who
survived or those who died. This is consistent with the ﬁndings of
Manesis et al.22 and Brunetto et al.23 The reason for the slow
decline in HBsAg in lamivudine treatment is probably because it
inhibits only the reverse transcription of the pre-genomic RNA but
does not target the ccc DNA directly.
On the other hand, HBsAg levels in the patients who survived
were signiﬁcantly higher than those of the patients who died, both
pre- and post-treatment (all p < 0.05) (Table 1). The ratio of post-
treatment HBsAg increasing in the survivors was signiﬁcantly
higher than that of the patients who died (Chi-square = 4.157,
p = 0.041). Furthermore, the 12-week survival rate of patients with
pretreatment HBsAg levels 4000 COI was signiﬁcantly higher
than that of cases with levels <4000 COI (Chi-square = 5.991,
p = 0.014) (Table 3). In HBeAg-negative ACLF, precore or basal core
promoter mutations of HBV promote virus replication and this may
be a key factor in the initiation of ACLF, however the cytokine-
induced secondary immunological lesion may be more important
in disease progression.4,5,24 The synthesis of HBsAg protein occurs
in hepatocytes. Therefore, the HBsAg level may indirectly reﬂect
the number of hepatocytes remaining. The lower pretreatment
HBsAg level reﬂects the fact that the patient has fewer hepatocytes
at baseline. The decline in post-treatment levels of HBsAg is not
only due to inhibition of HBV DNA replication by lamivudine, but
also reﬂects the degree of parenchyma replacement by necrosis
and a reduction in the number of hepatocytes, which results from
cytokine-induced secondary immunological lesions. This could be
the reason why the condition of some patients deteriorated even
though levels of HBsAg and HBV DNA decreased. The livers of the
patients with the lower post-treatment HBsAg levels had already
undergone massive or sub-massive hepatic necrosis in the short-
term, resulting in a lower 12-week survival rate. Our results are
consistent with those of the study by Rastogi et al.,25 who reported
that liver histological ﬁndings were correlated with the prognosis.
The degree of parenchyma replacement by ﬁbrosis or necrosis was
correlated with the outcome in patients with ACLF.
Our study further conﬁrms the role of HBsAg in the
pathogenesis of HBeAg-negative ACLF. The serum HBsAg level
results from a balance between virus biology and the host’s
immune system, as well as the indirect expression of transcrip-
tionally active ccc DNA, rather than the product of viral replication,
which is consistent with the studies by Brunetto26 and Vigano and
Lampertico.27
Although lamivudine monotherapy is no longer recommended
as a ﬁrst-line nucleoside analog treatment, it continues to be a
choice for HBeAg-negative ACLF therapy. The results of this study,
although obtained in a small patient sample, suggest that the
HBsAg level could be a predictor in the management of patientstreated with lamivudine. If prospectively validated in a larger
patient cohort, HBsAg measurements would represent a useful
adjunct to optimize antiviral therapy, thereby saving resources and
obtaining better clinical results.
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